Nikon Corporation Healthcare Business UnitGlobal

Close

The ECLIPSE Ti2-I Motorized Inverted Microscope for ICSI/IMSI, specialized for use in micro-insemination in infertility treatment, wins “Awards for Excellence” at the 2024Nikkei Excellent Products and Services Awards

January 6, 2025

ECLIPSE Ti2-I Motorized Inverted Microscope for ICSI/IMSI

AMSTERDAM, THE NETHERLANDS – Nikon Europe B.V. (Nikon) is pleased to announce that the ECLIPSE Ti2-I Motorized Inverted Microscope for ICSI*1/IMSI*2, specialized for use in micro-insemination in infertility treatment, released in July 2024 has won the “Awards for Excellence” at the 2024Nikkei Excellent Products and Services Awards sponsored by Nikkei Inc.

By allowing the microscope settings to be automatically controlled via simple buttons and a touch screen close to the user's hands, the ECLIPSE Ti2-I has improved efficiency by reducing the steps required for microscope operation by approximately 75%*3. An alert function and bright, clear field of view support accurate microscope operation. This product has attracted attention as a groundbreaking solution that meets the growing needs for infertility treatment in each country.

  1. *1Intracytoplasmic Sperm Injection: A method of directly injecting sperm into an egg while checking it under a microscope.
  2. *2Intracytoplasmic Morphologically Selected Sperm Injection: A method of selecting sperm to be used for ICSI by using a high-magnification microscope to observe and evaluate the sperm's morphology and structure in more detail.
  3. *3Calculated based on the number of steps in an example workflow and compared with that of previous models. According to Nikon research.

Related links

About the Nikkei Excellent Products and Services Awards

The Nikkei Excellent Products and Services Awards are given annually to recognize particularly outstanding new products and services, and this year marks the 43rd time these awards have been presented. Nikkei Inc. independently selects the candidate products and services. The judging committee comprehensively evaluates the products and services based on six criteria: technological development, cost-effectiveness, contribution to business performance, growth potential, uniqueness, and impact on industry and society.

Comment from Tatsuya Yamaguchi, Nikon Executive Officer, General Manager of Healthcare Business Unit

We are very pleased that the ECLIPSE Ti2-I Motorized Inverted Microscope for ICSI/IMSI has won the “Awards for Excellence” at the 2024Nikkei Excellent Products and Services Awards.

Nikon has been involved in the field of in vitro fertilization for approximately 40 years, providing products that support embryologists*4 in many processes, including ICSI.

As the declining birthrate becomes a serious issue worldwide, the demand for infertility treatment is increasing in the United States*5, Europe*6, Japan and other regions, due to women’s advancement in the workforce and the trend towards later childbirth.

The increase in infertility treatments is putting a growing burden on embryologists who support the treatment, and there is a greater demand for yet further efficiency and improvement in accuracy in their work. By providing the ECLIPSE Ti2-I, Nikon will help to reduce the burden on embryologists and contribute to improving infertility treatment techniques and fertility rates.

We would like to continue to promote technological innovation in the medical field and provide new solutions that contribute to addressing the declining birthrate.

  1. *4A medical professional who cultivates and manages fertilized eggs and embryos.
  2. *5In the United States, infertility treatments have increased by approximately 2.3 times between 2012 and 2021. Calculated based on the Report on Fertility Clinic and National Summary of ART (Artificial Reproduction Technology) Fertility Clinic and National Summary Report.
  3. *6In Europe, infertility treatment has increased by approximately 1.8 times between 2011 and 2019. Calculated based on "ART in Europe, 2019: results generated from European registries by ESHRE" (Human Reproduction, 2023, 38(12), 2321–2338).

The information is current as of the date of publication. It is subject to change without notice.

Topics